content

Aimmuneโ€™s peanut succeeds at phase||| trials

U.S. drug developer Aimmune Therapeutics said on Tuesday its peanut allergy drug met the main goal of an eagerly awaited late-stage study, sending its...

Arix secures partnership with Ipsen

The deal gives Ipsen access to Arixโ€™ network of professional and scientific advisors, and the chance to invest in the firmโ€™s new and existing...

Richard Wolf Announces the Opening of New Office in Singapore

Richard Wolf, answering strong global demand for its high-performance endoscopic technology services, today announced plans to expand in Southeast Asia by opening its 15th...

AbbVie and Voyager Therapeutics collaborates for Neurodegenerative Diseases

AbbVie , a global biopharmaceutical company, and Voyager Therapeutics, Inc. , a clinical-stage gene therapy company announced that they have entered into an exclusive...

AbbVieโ€™s elagolix on a great roll in its PH3 trials

Clinical response was defined as menstrual blood loss volume of less than 80 mL during month six and a 50 percent or greater reduction...

Larotrectinib data published in The New England Journal of Medicine: Bayer

Bayer and Loxo Oncology, Inc., , a biopharmaceutical company from Stamford announced the publication in The New England Journal of Medicine (NEJM) of larotrectinib...

Reckitt Benckiser’s proposal to buy Pfizer makes sense says JP Morgan

Reckitt Benckiser Group PLC is attempting to buy Pfizer Incโ€™s consumer healthcare business and analysts at JP Morgan think a potential deal makes sense....

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read